Print Email

About Study Groups  |  Study Groups  |  Workshops  |  Surveys  |  Resources

MASCC Hemostasis Study Group


Chair: Carmen Escalante, MD ( - USA
Vice-Chair: Thomas Butler, MD ( - USA
Vice-Chair: Carme Font, MD ( - Spain

Study Group Minutes
2016 Minutes  - Annual Meeting - Adelaide, Australia

Mission and Goals

The mission of the Hemostasis Study Group is to provide guidance and guidelines to healthcare providers regarding bleeding and clotting complications in cancer patients from diagnosis to the end of life. The goals of the group are (1) an increased awareness of abnormalities in the coagulation system at the time of cancer diagnosis, through treatment, and at the end of life, and (2) an increased availability of evidence-based treatment to patients with bleeding or clotting complications during treatment and at the end of life. To these ends, the Group has set the following objectives:

  • To keep up to date with current guidelines regarding treating cancer patients with bleeding and clotting problems related to their disease;
  • To evaluate current guidelines for their merit and deficiencies in providing adequate treatment to cancer patients with coagulation problems;
  • To focus on anticoagulation treatment and quality of life in cancer patients in both hospital and hospice settings.

Research Highlights

Romiplostim for the Management of Chemotherapy-Induced Thrombocytopenia
Chemotherapy-induced thrombocytopenia (CIT) can interfere with the optimal course of chemotherapy by necessitating schedule delays and dosage reductions. Some patients experience more severe or persistent thrombocytopenia than others, and their responses are neither well understood nor predictable. Both the prevention and management of CIT are critical in order for patients to benefit fully from chemotherapy. Recently, Dr. Rekha Parameswaran and colleagues reported on the successful use of weekly romiplostim for reducing CIT. Their review included both response to romiplostim therapy and toxicity assessment.  Read more . . .

Outpatient Management of Pulmonary Embolism in Cancer
Dr. Carme Font and colleagues in Spain conducted a prospective cohort study to determine the feasibility of outpatient treatment for patients with cancer and sudden, symptomatic vs. incidental PE. They assessed thromboembolism recurrence, major bleeding, and all-cause mortality. The authors also compared the performance of four different prognostic scales in predicting mortality and identifying patients who might be treated at home. The results suggest that a large proportion of patients with cancer and PE can be safely treated as outpatients, particularly those with incidental PE. Read more . . .

2017 Workshop

2017 Annual Meeting Workshop, June 22, Washington, DC
Update on Venous Thromboembolism: Approach and Challenges
This workshop will bring together a multinational group of experts to review current evidence and needed knowledge in the area of cancer-associated venous thromboembolism (VTE). It will include discussions of the clinical challenges as well as promote the education of patients, providers, and family members. Highlights include VTE prevention in ambulatory cancer patients, management of long-term treatment, and new oral anticoagulants. The workshop will focus on best practices, as illustrated by case studies, and will include discussion and illustration of various approaches to educating and engaging patients in the treatment process. The workshop will also include a patient presenter, who will speak to the group about the challenges of VTE and quality of life. 

This workshop will be offered jointly by the following MASCC Study Groups: Education; Hemostasis.
Workshop Chairs: Carme Font, Carmen Escalante, Tom Butler, Paz Fernández-Ortega

Member Publications

Font C, Fernández-Avilés F, Calderon C, García-Fernández T, Arab N, Pineda E, et al. Home management of acute medical complications in cancer patients: a prospective pilot study. Support Care Cancer 2016 May;24(5):2129-37.

Fernandez-Martinez A, Font C, Selvi M, Viladot M, Paré L, Galván P. et al. Phlegmasia cerulea dolens and multiple recurrent thrombotic events as the presenting feature of EML4-ALK translocated non-small cell lung cancer. Cancer Treatment Communications, Feb, 2016.

Tancabelic J. “Recombinant Human Erythropoietin in Pediatric Cancer Patients.” Anemia During Cancer Workshop. Copenhagen, June, 2015.

Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015 Feb 10;33(5):465-71.

Font C, Carmona-Bayonas A, Plasencia JM, Calvo-Temprano D, Sánchez M, Jiménez-Fonseca P, Beato C, Biosca M, Vicente V, Otero R; en representación de los Investigadores del Proyecto EPIPHANY. [Pulmonary embolism in patients with cancer: foundations of the EPIPHANY study]  Med Clin (Barc). 2015 Jan;144 Suppl 1:31-7.  Spanish.

Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M; Spanish Society for Medical Oncology. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol. 2014 Dec;16(12):1079-90.

Carmona-Bayonas A, Fonseca PJ, Font C, Martínez-García J, Torrella F, Urrego E, et al. Bacteremia in adult cancer patients with apparently stable febrile neutropenia: data from a cohort of 692 consecutive episodes from a single institution. J Community Support Oncol. 2014 Sep;12(9):312-20.

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014 May;22(5):1217-22.

Font C, Carmona-Bayonas A, Fernández-Martinez A, Beato C, Vargas A, Gascon P, Otero R. Outpatient management of pulmonary embolism in cancer: Data on a prospective cohort of 138 consecutive patients. J Natl Compr Canc Netw. 2014 Mar 1;12(3).

Carmona-Bayonas A, Font C, de la Peña FA. Stress-induced hyperglycemia is a valuable biomarker in febrile neutropenia. Rev Bras Hematol Hemoter. 2013;35(1):12-4.

Parameswaran R, Tancabelic J. An International Healthcare Provider Survey of Venous Thromboembolism Prophylaxis Guidelines Awareness in Cancer. Oral Presentation, MASCC Meeting New York, June 2012.

Font C, Farrús B, Vidal L, Caralt TM, Visa L, Mellado B, et al. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol. 2011 Sep;22(9):2101-6.

Font C, Vidal L, Espinosa G, Tàssies D, Monteagudo J, Farrús B, et al. Solid cancer, antiphospholipid antibodies, and venous thromboembolism. Autoimmun Rev. 2011 Feb;10(4):222-7.


What's New in the Management of Blood Clots for Cancer Patients 
Richard J. Gralla, MD, Rekha Parameswaran, MD, David A. Slosky, MD, Carolyn Messner, DSW, MSW. 
This 2012 webcast on the management of blood clots for cancer patients is available at You can view the webcast online or download an MP3 file. Topics include new treatments for venous thromboembolism, clinical trials and treatment options, the role of the FDA, and new clinical management strategies.

Please contact the Study Group Chairs above with your questions.
MASCC Study Group Coordinator, Don Gubitosa